The outcome of marrow transplantation is largely determined by the effectiveness of the transplant preparative regimen. Nonetheless, there have been startlingly few randomized trials attempting to identify optimal regimens for specific conditions and, at present, no single approach has emerged as superior for the treatment of acute myeloid leukemia (AML) in the few trials that have been performed. Newer approaches that appear encouraging in phase II studies include substituting etoposide for cyclophosphamide, adding thiotepa to the traditional cyclophosphamide plus total body irradiation combination in the setting of T cell depletion, and using antibody-based targeted radiotherapy as part of the transplant regimen. The ability to obtain allogeneic engraftment with nonablative regimens may open the door to additional innovative approaches, combining very specific antileukemia therapy with relatively nontoxic measures to ensure engraftment. Leukemia (2000) 14, 497-501.
Introduction
The effectiveness of transplantation for acute myeloid leukemia (AML) is likely heavily influenced by the choice of transplant preparative regimen. Yet there have been very few randomized trials performed comparing existing regimens. The need for randomized trials is emphasized by the number of factors that may impact on the outcome of transplantation. The following discussion considers those factors, offers a review of the randomized trials that have been performed to date, and suggests ways in which progress might be made in the development of new approaches to transplantation for AML.
Factors influencing the effectiveness of a given preparative regimen
Many factors likely influence the effectiveness of a particular regimen for preparing patients with AML for transplantation. Patient-specific characteristics, the nature of the specific leukemia, the source of stem cells, and the forms of graft-versushost disease (GVHD) prophylaxis and supportive care methods employed, all almost certainly affect the results obtained with any particular regimen. Some of these interactions have been formally addressed, but evidence for most are based on retrospective or anecdotal observations.
Patient-specific characteristics
The patient's age has an important influence on the ability to tolerate a particular regimen. 1 This is particularly true in the allogeneic setting where it has been demonstrated convincingly that the incidence of acute GVHD increases with age. A second important characteristic is the patient's overall health. Patients who come to transplant with evidence of prior liver disease as evidenced by elevated liver function tests, for example, have a higher incidence of veno-occlusive disease and cannot tolerate the same preparative regimen as a patient with a normally functioning liver. 4 Extent of previous therapy is an additional patient-specific characteristic with important implications for the impact of a particular regimen. It is known that patients with prior radiation therapy to the chest have a higher incidence of interstitial pneumonia if exposed to total body irradiation (TBI). 5 Using a non-TBI-containing regimen can spare patients of that toxicity. 6 Other less well understood patient-specific characteristics such as genetic polymorphisms for DNA repair are likely to become increasingly important in our understanding of transplantation. An extreme example of this category of characteristic is in Fanconi anemia. Because of genetically determined ineffective DNA repair, these patients cannot tolerate the same aggressive preparative regimen that an unaffected patient might easily tolerate. It is very likely that there are many minor variations on this theme and that in time we will be able to genotype patients to help select the category and dose of drug most appropriate for them.
Nature of disease
The character of the leukemia under treatment influences the relative effectiveness of a specific transplant regimen. Patients in remission at the time of transplant may benefit from a less aggressive preparative regimen than a patient in full relapse where the increased toxicity of a more intensive preparative regimen may be more than balanced by a diminished relapse rate. Other molecular characteristics of a patient's particular form of AML may influence the effectiveness of the preparative regimen. Patients whose disease expresses multidrug resistance (MDR) to a high degree may not benefit from the addition of an anthracycline or etoposide to the preparative regimen compared to patients whose disease does not express MDR. The reverse may be true for patients with relapsed acute promyelocytic leukemia, a disease known to be very sensitive to anthracyclines, who may specifically benefit from the inclusion of anthracyclines to their regimen.
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Source of stem cells
Patients who receive autologous or matched sibling stem cell transplants can tolerate a more aggressive preparative regimen than can recipients of marrow from an unrelated donor. Studies performed at our institution several years ago demonstrate increased regimen-related toxicity in the unrelated setting compared to the amount seen with the use of an identical preparative regimen in patients transplanted from matched siblings.
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GVHD prophylaxis
The exclusion of methotrexate from post-transplant immunosuppression reduces the amount of mucositis and therefore may allow patients to tolerate more aggressive preparative regimens.
Supportive care
Randomized trials evaluating the use of hematopoietic growth factors post-transplant suggest that more rapid hematopoietic recovery results not only in fewer days with infection, but also a lower incidence of other toxicities. 10 Nonrandomized trials using peripheral blood stem cells suggest similar results.
Randomized clinical trials
Given the numbers of factors that influence the outcome of transplantation, it is reasonable to assume that no single preparative regimen will be superior for every individual and every circumstance. Therefore, when evaluating preparative regimens, it is important to do so in defined settings and it would be optimal to conduct such comparisons as randomized trials in order to diminish the impact of the above noted variables. Unfortunately, to date there have been very few randomized trials evaluating preparative regimens in marrow transplantation (Table 1) .
In the setting of HLA-identical allogeneic transplantation for AML in first remission, two randomized studies comparing different doses of total body irradiation combined with a set dose of cyclophosphamide (CY) have been performed. One study showed that 12 Gy of fractionated TBI was superior to 10 Gy of TBI delivered as a single dose. 11 A second study compared 12 Gy of fractionated TBI to 15.75 Gy of TBI and showed that the overall outcome of these two approaches was equivalent although for different reasons. 12 There was a lower relapse rate with the higher dose of TBI than with the lower dose, but there was a higher incidence of nonrelapse mortality with the higher dose with the result that overall, the two approaches provided equivalent long-term survival.
There are two randomized studies of preparative regimens for allogeneic transplantation for AML in first remission that examined issues other than TBI dose. In one study, CY plus TBI was compared to melphalan plus TBI and the two regimens were found to be equivalent. 13 Another study compared CY plus TBI with busulfan (BU) plus CY in 101 patients with AML in first remission receiving matched sibling transplants. 14 The relapse rate was found to be significantly lower in the CY plus TBI arm than in the BU plus CY arm resulting in an over- 
Figure 1
Actuarial probability of disease-free survival among 101 patients randomized to either CY-TBI (n = 50) or BU-CY (n = 51). 14 all improved disease-free survival with CY plus TBI (Figure 1 ). The outcome with CY plus TBI (72% disease-free survival) was somewhat higher than had been seen historically with this regimen. Whether the improved outcome with CY plus TBI reflects real superiority of this regimen over BU plus CY or an unusually fortunate outcome for one arm in this particular study is uncertain. Data have since been published from the European Bone Marrow Transplant Group (EBMT) trying to address this issue. Ringdén et al 15 identified 223 patients with AML in first CR transplanted after a regimen of CY plus TBI and 223 matched controls who were transplanted with BU plus CY. They found virtually identical transplant-related mortality, relapse rates and disease-free survival at 3 years in the two groups (Figure 2) . Thus, the difference first suggested by the French study has not been substantiated when larger numbers of patients have been studied, albeit in a nonrandomized registry exercise.
Figure 2
Actuarial probability of disease-free survival in 223 patients with AML in first remission treated with BU-CY compared to results seen in 223 patients treated with CY-TBI.
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These four studies represent the only randomized trials of preparative regimens for allogeneic transplantation for AML in first remission published to date. A prospective randomized trial conducted by the Southwest Oncology Group compared BU plus CY with etoposide plus TBI in patients with leukemia beyond first remission undergoing allogeneic transplantation. The study included patients with acute lymphoblastic and chronic myelogenous leukemia, as well as AML. Overall, there was no significant difference in outcomes between the two regimens, although there was a trend toward improved outcomes with the etoposide-TBI regimen in patients with 'good risk' disease. 16 The number of randomized studies of preparative regimens for autologous transplantation are even fewer, with only one randomized study of preparative regimens for AML in first remission. There was a very small trial from Minnesota looking at BU plus CY vs CY plus TBI. 17 With only 20 patients in each arm, the power of the study was very small. In order to obtain information from larger numbers of patients, the EBMT compared historical data with BU plus CY vs CY plus TBI and, as in the case of allogeneic BMT, found that the outcomes of these two preparative regimens were virtually identical.
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Clinical trials: approaches under development
A number of encouraging phase II trials of preparative regimens for patients with AML in first remission have been published, but none of these approaches has yet been tested in prospective randomized trials. The group from City of Hope has combined VP16 with TBI and has seen long-term diseasefree survival of about 60%. 18 Whether this is superior to results obtained with BU plus CY or CY plus TBI is untested. Another approach piloted by the Sloan-Kettering group in 31 patients involves the use of lectin-based T cell depletion of marrow and a preparative regimen of cyclophosphamide, thiotepa and fractionated TBI. 19 In this approach, with T cell depletion, no post-transplant immunosuppression was given which may have permitted the administration of the more intense preparative regimen. Although only a limited number of patients has been treated, the results are encouraging with 70% alive, many of these beyond 2 years from transplant.
An approach being studied at the Fred Hutchinson Cancer Research Center is based on the outcome of the randomized trial that showed a lower relapse rate using 15.75 Gy vs 12 Gy of TBI, but a higher incidence of transplant-related mortality with the higher dose of TBI. We hypothesize that if radiotherapy could be targeted specifically to sites of leukemia, we might be able to take advantage of the apparently steep doseresponse curve to radiation without the increased treatmentrelated mortality. We developed an approach using 131 I anti-CD45 radiolabeled antibody to deliver radiation specifically to marrow. In an earlier study, we showed that with this approach we could deliver three-to four-fold more radiation to hematopoietic tissues as compared to normal organs such as lung, liver and kidney. 20 A current trial involves patients with AML in first remission receiving transplants from matched siblings following a standard preparative regimen of BU (16 mg/kg) plus CY (120 mg/kg) with a supplemental dose of radiation using an anti-CD45 antibody radiolabeled with 131 I. Each patient is given a trace-labeled dose of the anti-CD45 antibody to determine how much radiation would be delivered to marrow and normal organs. This trace dose is used to determine how much 131 I to label the antibody with in order to deliver the Leukemia planned dose of radiation to normal organs and marrow. We have now treated 27 patients on this study and the diseasefree survival is approximately 80% with this regimen with a maximum follow-up of over 4 years. This phase II study needs to accumulate more patients, but if the results persist we plan a randomized phase III trial comparing BU/CY with BU/CY plus 131 I-labeled anti-CD45 antibody. Most of the studies conducted to date have considered the transplant preparative regimen as a single entity of high-dose chemoradiotherapy that has the dual responsibilities of ablating the diseased marrow, as well as immunosuppressing the patient adequately to allow for successful transplantation. This view is now changing. We have carried out a series of studies in which we have asked how much radiation is needed to ensure allogeneic engraftment. Storb et al 21 previously showed that to achieve engraftment of marrow in DLA-identical dogs, if no transplant immunosuppression is given, administration of almost 1000 cGy of radiation is required. This is why 1000 cGy was used in the very early human transplants.
However, it has become clear that post-transplant immunosuppression is fundamentally important in determining how much radiation is required to achieve engraftment. At a dose of 450 cGy, 40% of animals engraft with DLA-matched marrow if no post-transplant immunosuppression is given. If cyclosporine is given post-transplant, 100% engraftment can be achieved in DLA-identical dogs at that same dose of TBI. 21 As the TBI dose is lowered below 450 cGy with just cyclosporine as post-transplant immunosuppression, again graft rejections develop. If a combination of cyclosporine plus another immunosuppressant, mycophenolate mofetil, is administered, engraftment can be achieved in virtually all dogs with only 200 cGy of TBI.
A dose of 200 cGy is nonmyeloablative and can be given to most patients with minimal side-effects. On this basis, we have been studying the clinical impact of allogeneic transplantation following a nonablative transplant preparative regimen consisting of a single dose of 200 cGy of TBI with cyclosporine and mycophenolate mofetil as post-transplant immunosuppression. Results were presented on 11 patients at the American Society of Hematology in December, 1998. 22 Of these, nine of 11 achieved engraftment. The two who failed to engraft had multiple myeloma, had received very little pretransplant therapy, and apparently had a more intact immune system. This study has now been expanded to over 30 patients and the two myeloma patients plus one patient with CML are the only patients who have rejected their grafts. Ten patients with AML have now been engrafted with 200 cGy of TBI and post-transplant cyclosporine and mycophenolate mofetil. All are over age 55, had incomplete remissions or were in early relapse, and would not have been candidates for normal allogeneic transplants.
The ability to achieve engraftment with nonablative regimens allows us to be able to segregate the transplant preparative regimen into those elements that are directed to the eradication of leukemia without having to worry about their immunosuppressive effects and combine these elements with a nonablative regimen designed to ensure engraftment. In addition, it may become possible to isolate T cells from the donor, clone those that are quite specific for leukemia-associated antigens and infuse them to the patient post-transplant without toxicity. This has been achieved in the setting of cytomegalovirus (CMV) where CMV seropositive patients entering transplantation have a high incidence of reactivation of CMV unless given ganciclovir post-transplant. Walters and col-leagues 23 have shown that it is possible to isolate T cells reactive with CMV from the donor, expand them to large numbers and administer these cells to the patient post-transplant. In a series of 30 patients, it was shown that this could be accomplished without toxicity because the cells are CMVspecific and do not cause GVHD. Individuals receiving such cells were entirely protected from developing CMV disease.
The preparative regimen of the future may look considerably different from those used today. Instead of relying on very high-dose nonspecific chemotherapy with or without TBI, we will target our therapy specifically to the leukemia without concern for its immunosuppressive properties. Specific immunosuppression with little other toxicity will be used to allow for engraftment. Finally, in the post-transplant setting, techniques will be developed to achieve selective immune reconstitution to decrease recurrence of malignancy and improve immunity against pathogens.
